Evidence map›Paper›PMID 38072400›Full record

ReviewJournal of gynecologic oncology2024

Recent breakthroughs in the management of locally advanced and recurrent/metastatic cervical cancer.

Eduardo García, Natalie Ayoub, Krishnansu S Tewari

Erratum issuedOpen access · diamondAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of gynecologic oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 14 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 3 pooled it
5.0field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 3 syntheses or guidelines pooled it, 17 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Are we making progress in curing advanced cervical cancer-again?International journal of gynecological cancer : official journal of the International Gynecological Cancer Society · 2024
    Review
  12. Review
  13. Article
  14. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Eduardo GarcíaUniversity California, Irvine, Medical Center, Orange, CA, USA. egarci17@hs.uci.edu.ORCID 0000-0002-8334-1382
Natalie AyoubAdventist Health White Memorial, Medical Center, Los Angeles, CA, USA.ORCID 0000-0003-2931-5834
Krishnansu S TewariUniversity California, Irvine, Medical Center, Orange, CA, USA.ORCID 0000-0002-8417-7000
University of California, Irvine Medical Center · USWhite Memorial Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cervical cancer continues to be a global threat affecting individuals in resource poor communities disproportionately. The treatment paradigm for this disease is ever evolving with recent innovations propelling oncologic outcomes to a new frontier offering survival benefits for patients struggling with locally advanced disease and metastatic/recurrent carcinoma. Immunologic checkpoint inhibitors and anti-body drug conjugates represent two novel drug classes that have demonstrable activity in this disease, particularly in the first-line and second-line treatment paradigm for recurrence. The tolerability of these novel medicines and associated durable responses underscore regulatory approval by the U.S. Food and Drug Administrations and their implementation in clinic.

Indexed as

Uterine Cervical NeoplasmsFemaleHumansImmunotherapyNeoplasm Recurrence, LocalAntibody Drug ConjugateCervical CancerChemoradiationImmune Checkpoint InhibitorImmunotherapy

Identifiers

PMID38072400
PMCPMC10792211
OpenAlexW4389356547

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.